Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and Insertion of the selection cassette in exon1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-EIF3H, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
EIF3H also known as eukaryotic translation initiation factor 3 subunit H is a component of the eIF3 complex which plays a substantial role in translation initiation. The protein possesses a molecular mass of approximately 42 kDa. EIF3H is broadly expressed in various tissues and cells including high expression levels in proliferating cells. The protein is part of the larger eIF3 complex which consists of 13 subunits contributing to the formation of the pre-initiation complex essential for mRNA translation.
Biological function summary
EIF3H facilitates the recruitment of mRNA to the ribosome by stabilizing the interaction between mRNA and the 40S ribosomal subunit. It functions within the eIF3 complex to assist in ribosomal scanning and the start codon selection. As part of this complex EIF3H helps govern the efficiency of translation initiation impacting protein synthesis rates. These activities are important for cell growth and protein expression regulation underlying the complex's importance in cellular processes.
Pathways
EIF3H plays a role in the mTOR signaling pathway and the MAPK/ERK pathway both extensively involved in regulating cell growth and proliferation. Through these pathways EIF3H interacts with proteins such as eIF4G and ribosomal protein S6 which help coordinate the translation machinery's function and cellular metabolic control. These pathways highlight EIF3H's role in translational control affecting overall cellular function.
EIF3H is implicated in cancer particularly in types characterized by unchecked cellular proliferation such as lung and breast cancer. EIF3H's dysregulated expression or activity can influence oncogenic pathways leading to malignancies. Additionally EIF3H interacts with proteins like c-Myc a well-known oncogene through its involvement in cancer pathways. These associations highlight EIF3H as a potential target for therapeutic intervention in cancer treatments.
